WVE Stock Forecast & Price Target

Wave Life Sciences is viewed positively because its PRISM platform and broad RNA-medicine toolkit position it to pursue multiple high-value programs across rare and prevalent diseases, while its strong IP creates meaningful freedom to operate in a competitive nucleic-acid space. The company’s lead assets show tangible promise: WVE-007 posted positive obesity data from Ph1 INLIGHT, and WVE-006 demonstrated subcutaneous monthly dosing, 67.7%–70.5% Z-AAT reductions, and statistically significant biomarker support with CRP correlation of r=0.73 (p<0.001, n=19). Despite tougher competition in AATD, the analyst still sees upside from probability-adjusted revenues, a DCF to 2040, and near-term regulatory catalysts, including mid-2026 FDA accelerated-approval feedback and a 2026 NDA submission for WVE-N531.

Wave Life Sciences is viewed negatively because the thesis depends on an early-stage pipeline with higher-than-average clinical, regulatory, commercial, and manufacturing risk, leaving limited fundamental support until multiple programs prove successful. The reduced PoS assumptions and lower penetration expectations for WVE-006 signal weaker confidence in the company’s lead opportunity, while the valuation framework still relies on stretched FY34 GAAP EPS of $1.85 and an NPV-based estimate that is highly sensitive to discounting and growth assumptions. With key downside risk tied to failures in WVE-007, WVE-006, WVE-003, and WVE-N531 in clinical studies, regulatory approval, or commercial uptake, the company’s outlook remains fragile and heavily execution-dependent.